Cogent Biosciences Stock Filter Stocks by Fundamentals
| COGT Stock | USD 7.64 0.55 6.72% |
Cogent Biosciences fundamentals help investors to digest information that contributes to Cogent Biosciences' financial success or failures. It also enables traders to predict the movement of Cogent Stock. The fundamental analysis module provides a way to measure Cogent Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cogent Biosciences stock.
Cogent | Shares Owned by Institutions |
Cogent Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cogent Biosciences from analyzing Cogent Biosciences' financial statements. These drivers represent accounts that assess Cogent Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cogent Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 21.9M | 124.4M | 332.3M | 679.0M | 611.1M | 641.7M | |
| Enterprise Value | (9.4M) | (112.5M) | 115.8M | 558.8M | 502.9M | 528.1M |
Cogent Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cogent Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cogent Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cogent Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cogent Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cogent Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cogent Biosciences' value.| Shares | Adage Capital Partners Gp Llc | 2024-09-30 | 4.1 M | Deerfield Management Co | 2024-09-30 | 3.7 M | State Street Corp | 2024-09-30 | 3.2 M | Geode Capital Management, Llc | 2024-09-30 | 2.3 M | Sofinnova Ventures | 2024-09-30 | 2.3 M | Logos Global Management Lp | 2024-09-30 | 2 M | Saturn V Capital Management Llc | 2024-09-30 | 1.7 M | Millennium Management Llc | 2024-09-30 | 1.6 M | Octagon Capital Advisors Lp | 2024-09-30 | 1.3 M | Point72 Asset Management, L.p. | 2024-09-30 | 10.5 M | Kynam Capital Management, Lp | 2024-09-30 | 9.2 M |
Cogent Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 636.84 M | ||||
| Shares Outstanding | 110.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 99.88 % | ||||
| Number Of Shares Shorted | 8.42 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 4.14 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (205.86 M) | ||||
| Net Income | (192.41 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 18.85 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (153.62 M) | ||||
| Short Ratio | 5.91 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 16.8 | ||||
| Number Of Employees | 164 | ||||
| Beta | 0.021 | ||||
| Market Capitalization | 843.93 M | ||||
| Total Asset | 313.44 M | ||||
| Retained Earnings | (603.62 M) | ||||
| Working Capital | 232.6 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
| Net Asset | 313.44 M |
About Cogent Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.